Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 20:8:102.
doi: 10.3389/fneur.2017.00102. eCollection 2017.

Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid

Rose Ann Huynh  1 , Chandra Mohan  1
Affiliations
Review

Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid

Rose Ann Huynh et al. Front Neurol. .

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 million are affected globally with numbers reaching 115 million by 2050. AD can only be definitively diagnosed at autopsy since its manifestations of senile plaques and neurofibrillary tangles throughout the brain cannot yet be fully captured with current imaging technologies. Current AD therapeutics have also been suboptimal. Besides identifying markers that distinguish AD from controls, there has been a recent drive to identify better biomarkers that can predict the rates of cognitive decline and neocortical amyloid burden in those who exhibit preclinical, prodromal, or clinical AD. This review covers biomarkers of three main types: genes, cerebrospinal fluid-derived, and blood-derived biomarkers. Looking ahead, cutting-edge OMICs technologies, including proteomics and metabolomics, ought to be fully tapped in order to mine even better biomarkers for AD that are more predictive.

Keywords: Alzheimer’s disease; blood-derived biomarkers; early detection; genetic biomarkers; longitudinal studies; neurochemical biomarkers.

PubMed Disclaimer

References

    1. Alzheimer’s Association. Alzheimer’s Disease Facts and Figures. (2013). Available from: https://www.alz.org/downloads/facts_figures_2013.pdf
    1. Alzheimer’s Disease Education and Referral (ADEAR) Center. Alzheimer’s Disease Fact Sheet. NIH Publication No. 11-6423 (2011). Available from: https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-s...
    1. Galluzzi S, Geroldi C, Amicucci G, Bocchio-Chiavetto L, Bonetti M, Bonvicini C, et al. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J Neurol (2013) 260:640–50. 10.1007/s00415-012-6694-0 - DOI - PubMed
    1. Murphy MP, Levine H., III Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 19:311–23. 10.3233/JAD-2009-1221 - DOI - PMC - PubMed
    1. Baird AL, Westwood S, Lovestone S. Blood-based proteomic biomarkers of Alzheimer’s disease pathology. Front Neurol (2015) 6:236. 10.3389/fneur.2015.00236 - DOI - PMC - PubMed